IONS
Price
$43.78
Change
+$0.93 (+2.17%)
Updated
Aug 15 closing price
Capitalization
6.98B
73 days until earnings call
XENE
Price
$38.23
Change
+$0.27 (+0.71%)
Updated
Aug 15 closing price
Capitalization
2.95B
79 days until earnings call
Interact to see
Advertisement

IONS vs XENE

Header iconIONS vs XENE Comparison
Open Charts IONS vs XENEBanner chart's image
Ionis Pharmaceuticals
Price$43.78
Change+$0.93 (+2.17%)
Volume$1.6M
Capitalization6.98B
Xenon Pharmaceuticals
Price$38.23
Change+$0.27 (+0.71%)
Volume$820.1K
Capitalization2.95B
IONS vs XENE Comparison Chart in %
Loading...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IONS vs. XENE commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (IONS: $43.78 vs. XENE: $38.23)
Brand notoriety: IONS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IONS: 80% vs. XENE: 69%
Market capitalization -- IONS: $6.98B vs. XENE: $2.95B
IONS [@Biotechnology] is valued at $6.98B. XENE’s [@Biotechnology] market capitalization is $2.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IONS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IONS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IONS’s TA Score shows that 3 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • IONS’s TA Score: 3 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, XENE is a better buy in the short-term than IONS.

Price Growth

IONS (@Biotechnology) experienced а +5.14% price change this week, while XENE (@Biotechnology) price change was +14.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

IONS is expected to report earnings on Oct 30, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.98B) has a higher market cap than XENE($2.95B). IONS YTD gains are higher at: 25.229 vs. XENE (-2.474). IONS has higher annual earnings (EBITDA): -170.69M vs. XENE (-290.36M). IONS has more cash in the bank: 2.29B vs. XENE (550M). XENE has less debt than IONS: XENE (8.68M) vs IONS (1.42B). IONS has higher revenues than XENE: IONS (944M) vs XENE (7.5M).
IONSXENEIONS / XENE
Capitalization6.98B2.95B237%
EBITDA-170.69M-290.36M59%
Gain YTD25.229-2.474-1,020%
P/E RatioN/AN/A-
Revenue944M7.5M12,587%
Total Cash2.29B550M416%
Total Debt1.42B8.68M16,369%
FUNDAMENTALS RATINGS
IONS vs XENE: Fundamental Ratings
IONS
XENE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
4444
P/E GROWTH RATING
1..100
666
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (75) in the Biotechnology industry is in the same range as IONS (95). This means that XENE’s stock grew similarly to IONS’s over the last 12 months.

XENE's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for IONS (100). This means that XENE’s stock grew somewhat faster than IONS’s over the last 12 months.

XENE's SMR Rating (96) in the Biotechnology industry is in the same range as IONS (98). This means that XENE’s stock grew similarly to IONS’s over the last 12 months.

XENE's Price Growth Rating (44) in the Biotechnology industry is in the same range as IONS (44). This means that XENE’s stock grew similarly to IONS’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is somewhat better than the same rating for IONS (66). This means that XENE’s stock grew somewhat faster than IONS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IONSXENE
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bearish Trend 5 days ago
76%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
64%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 13 days ago
68%
Bearish Trend 11 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
78%
Aroon
ODDS (%)
Bullish Trend 4 days ago
67%
Bearish Trend 4 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGIAX10.440.03
+0.29%
Russell Inv Global Infrastructure A
GGOIX23.00-0.02
-0.09%
Goldman Sachs Mid Cap Growth Instl
TDVFX15.09-0.02
-0.13%
Towle Value
VITNX107.62-0.29
-0.27%
Vanguard Instl Ttl Stk Mkt Idx I
PSCZX24.49-0.12
-0.49%
PGIM Jennison Small Company Z

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
+2.17%
ALNY - IONS
56%
Loosely correlated
+1.40%
IDYA - IONS
51%
Loosely correlated
-0.16%
IMVT - IONS
49%
Loosely correlated
N/A
BEAM - IONS
48%
Loosely correlated
+1.08%
CRNX - IONS
48%
Loosely correlated
N/A
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.71%
IDYA - XENE
57%
Loosely correlated
-0.16%
CRNX - XENE
54%
Loosely correlated
N/A
NRIX - XENE
51%
Loosely correlated
+0.19%
IMVT - XENE
51%
Loosely correlated
N/A
IONS - XENE
50%
Loosely correlated
+2.17%
More